School of Medicine


Showing 11-20 of 272 Results

  • Ahmad Salehi, M.D., Ph.D.

    Ahmad Salehi, M.D., Ph.D.

    Adjunct Professor, Psych/Public Mental Health & Population Sciences

    Bio Dr. Salehi is a neurobiologist working on identifying molecular mechanisms of neurodegenerative disorders including Alzheimer's disease and Down syndrome. In this process, ?he uses pre-clinical experiments to test the effects of already-approved drugs in improving cognitive function in the mouse models with hippocampal degeneration. In 2010, he received the World Technology Award for the innovative use of mouse models of Down syndrome to identify genes responsible for cognitive disabilities. Recently, he found that increasing beta2 adrenergic signaling would improve cognitive function in a mouse model of Down syndrome. Accordingly, in a collaborative study, he is testing whether already-approved beta2-adrenergic receptor agonists can indeed improve cognitive function and reduce the severity of pathology in individuals with mild to moderate Alzheimer?s disease.

    Selected Publications

    Dang V, Medina B, Das D, Moghadam S, Martin KJ, Lin B, Naik P, Patel D, Nosheny R, Wesson Ashford J, Salehi A. Formoterol, a long-acting ?2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome. Biol Psychiatry. 2014 Feb 1;75(3):179-88. doi: 10.1016/j.biopsych.2013.05.024. PMID: 23827853

    Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, Kleschevnikov A, Wagner SL, Aisen P, Shamloo M, Mobley WC. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med. 2009 Nov 18;1(7):7ra17. doi: 10.1126/scitranslmed.3000258.? ?PMID: 20368182
    Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, Xia W, Villar A, Campbell WA, Kulnane LS, Nixon RA, Lamb BT, Epstein CJ, Stokin GB, Goldstein LS, Mobley WC. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron. 2006 Jul 6;51(1):29-42.? ?PMID: 16815330

    Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, Xia W, Villar A, Campbell WA, Kulnane LS, Nixon RA, Lamb BT, Epstein CJ, Stokin GB, Goldstein LS, Mobley WC.Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.
    Neuron. 2006 Jul 6;51(1):29-42.

    Links:
    Lab: www.ahmadsalehi.info
    Linkedin: https://www.linkedin.com/in/ahmadsalehi1/
    Scholar: https://scholar.google.com/citations?user=Wr3FcsEAAAAJ&hl=en

  • Denis Noel Salins

    Denis Noel Salins

    Temp - Non-Exempt, Genetics

    Bio Denis is a software developer at his core who loves to dabble on the cutting edge of technology. He has a passion for how technology and software and add value to everyday life and with simplicity and grace and empower users to do more with less frustration. Denis loves the intersection of Health and Technology and wants to make contributions to to the betterment of society and community with meaningful technology. For Denis the adoption of technology to allow humans to live longer, live better, and/or improve life, is the driving force.

    Prior to Stanford, Denis has been an active part of many companies, large and small, and enjoys the entrepreneurial spirit. He was a core developer for First Medical Solutions electronic medical records software platform. He developed middleware systems to manage integration and interoperability. He also likes to explore hardware projects with Raspberry Pi.

Footer Links:

Stanford Medicine Resources: